1009 related articles for article (PubMed ID: 23589621)
1. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
2. Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.
Chi Y; Fan Y; He L; Liu W; Wen X; Zhou S; Wang X; Zhang C; Kong H; Sonoda L; Tripathi P; Li CJ; Yu MS; Su C; Hu G
Aging Cell; 2011 Jun; 10(3):368-82. PubMed ID: 21255222
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.
Depboylu C; Schorlemmer K; Klietz M; Oertel WH; Weihe E; Höglinger GU; Schäfer MK
J Neuroimmunol; 2011 Jul; 236(1-2):39-46. PubMed ID: 21640391
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress.
Luk KC; Rymar VV; van den Munckhof P; Nicolau S; Steriade C; Bifsha P; Drouin J; Sadikot AF
J Neurochem; 2013 Jun; 125(6):932-43. PubMed ID: 23331067
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
7. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
8. Dopamine Receptor D3 Expression Is Altered in CD4
Elgueta D; Contreras F; Prado C; Montoya A; Ugalde V; Chovar O; Villagra R; Henríquez C; Abellanas MA; Aymerich MS; Franco R; Pacheco R
Front Immunol; 2019; 10():981. PubMed ID: 31118938
[TBL] [Abstract][Full Text] [Related]
9. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2002 Sep; 16(11):1474-6. PubMed ID: 12205053
[TBL] [Abstract][Full Text] [Related]
10. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
11. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.
Reynolds AD; Banerjee R; Liu J; Gendelman HE; Mosley RL
J Leukoc Biol; 2007 Nov; 82(5):1083-94. PubMed ID: 17675560
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R
Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
16. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Hwang CJ; Choi DY; Jung YY; Lee YJ; Yun JS; Oh KW; Han SB; Oh S; Park MH; Hong JT
Horm Behav; 2016 Apr; 80():19-29. PubMed ID: 26836768
[TBL] [Abstract][Full Text] [Related]
18. Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease.
Zhang J; Yang B; Sun H; Zhou Y; Liu M; Ding J; Fang F; Fan Y; Hu G
Neurosci Lett; 2016 Feb; 614():7-15. PubMed ID: 26748031
[TBL] [Abstract][Full Text] [Related]
19. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
20. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease.
Dutta D; Kundu M; Mondal S; Roy A; Ruehl S; Hall DA; Pahan K
Neurobiol Dis; 2019 Dec; 132():104575. PubMed ID: 31445159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
